The price of amivantamab in 2025

Amivantamab is a new bispecific monoclonal antibody that mainly targets the EGFR and MET receptor pathways. It is designed to treat patients with non-small cell lung cancer (NSCLC) carrying EGFR exon 20 insertion mutations. Patients with this type of mutant lung cancer have limited response to conventional EGFR inhibitors, so the development of evantumumab filled this clinical gap. As a biologic, it inhibits tumor cell growth and spread by blocking signaling pathways and inducing antibody-dependent cytotoxicity. Its indications focus on patients whose disease has progressed despite previous systemic treatment, providing a new treatment option for advanced or drug-resistant patients.

In terms of price, evantumumab has been approved for marketing in China, but it has not yet been included in medical insurance, so patients need to pay for it at their own expense. The current common specification on the market is 350mg, and the price per box is about more than 7,000 yuan. The Hong Kong version of the original drug is priced at about more than 8,000 yuan. In comparison, the price in the European market is higher, and the price per box may reach about 20,000 yuan, and the price will fluctuate due to exchange rate changes. This difference is closely related to market supervision, channel circulation and pricing strategies. It is worth noting that there are currently no generic drugs approved for marketing worldwide, so both domestic and overseas patients still mainly use original drugs.

With the popularity of innovative anti-cancer drugs and policy promotion around the world, evantumumab may have the opportunity to be included in reimbursement in future medical insurance negotiations, which will significantly reduce the financial burden on patients. At the same time, with the expansion of production scale and competition in multi-national markets, its prices may gradually decline in the future. For patients with EGFR exon 20 insertion mutations, this drug is undoubtedly a milestone in the treatment landscape, especially in the context of the lack of effective targeted drugs, providing practical clinical benefits.

Reference materials:https://www.rybrevant.com/